Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 29Active not recruiting 13Terminated 10Withdrawn 3Recruiting 3Approved for marketing 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 13INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Lymphoma 1Fallopian Tube Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × niraparib × Clear all
NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

AGO Research GmbH

Phase 2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04655183 2021-06-30

Study of M4344 in Combination With Niraparib

EMD Serono

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡